Drug Profile
Ertapenem - Merck & Co
Alternative Names: Ertapenem sodium; Invanz; L 749345; MK 0826; MK 826; ZD 4433Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Merck & Co
- Class Amides; Anti-infectives; Antibacterials; Benzoic acids; Carbapenems; Pyrrolidines; Small molecules; Sulfides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections; Obstetric and gynaecological infections; Skin and soft tissue infections; Urinary tract infections
Most Recent Events
- 27 Jul 2018 First generic equivalent available in USA
- 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote ertapenem in South Korea for Bacterial infections
- 01 Dec 2013 Merck Sharp & Dohme completes a phase III trial in Skin and soft tissue infections (in patients with diabetes mellitus) in China (NCT01370616)